Search Results - "MINKO, Tamara"

Refine Results
  1. 1

    Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 by Majumder, Joydeb, Minko, Tamara

    Published in The AAPS journal (05-01-2021)
    “…The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious…”
    Get full text
    Journal Article
  2. 2

    Nanotechnology approaches for inhalation treatment of lung diseases by Kuzmov, Andriy, Minko, Tamara

    Published in Journal of controlled release (10-12-2015)
    “…Local administration of therapeutics by inhalation for treatment of lung diseases has the ability to deliver drugs, nucleic acids and peptides specifically to…”
    Get full text
    Journal Article
  3. 3

    Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier by Lee, David, Minko, Tamara

    Published in Pharmaceutics (30-11-2021)
    “…Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders has always been a significant challenge. The nature of the blood-brain…”
    Get full text
    Journal Article
  4. 4

    Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery by Shen, Andrew M., Minko, Tamara

    Published in Journal of controlled release (10-10-2020)
    “…Pulmonary delivery of lipid-based nanotherapeutics by inhalation presents an advantageous alternative to oral and intravenous routes of administration that…”
    Get full text
    Journal Article
  5. 5

    Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA by Taratula, Oleh, Kuzmov, Andriy, Shah, Milin, Garbuzenko, Olga B., Minko, Tamara

    Published in Journal of controlled release (10-11-2013)
    “…We developed, synthesized, and tested a multifunctional nanostructured lipid nanocarrier-based system (NLCS) for efficient delivery of an anticancer drug and…”
    Get full text
    Journal Article
  6. 6

    Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations by Majumder, Joydeb, Minko, Tamara

    Published in Pharmaceutics (11-07-2021)
    “…Resistance to chemotherapy, enhanced proliferation, invasion, angiogenesis, and metastasis (RPIAM) represent major obstacles that limit the efficacy of cancer…”
    Get full text
    Journal Article
  7. 7

    Metastatic and triple-negative breast cancer: challenges and treatment options by Al-Mahmood, Sumayah, Sapiezynski, Justin, Garbuzenko, Olga B., Minko, Tamara

    Published in Drug delivery and translational research (01-10-2018)
    “…The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy…”
    Get full text
    Journal Article
  8. 8

    Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene Silencing by Patil, Mahesh L, Zhang, Min, Minko, Tamara

    Published in ACS nano (22-03-2011)
    “…A novel triblock poly(amido amine)-poly(ethylene glycol)-poly-l-lysine (PAMAM-PEG-PLL) nanocarrier was designed, synthesized, and evaluated for the delivery of…”
    Get full text
    Journal Article
  9. 9

    Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug-Resistant Cancer Cells by Chen, Alex M., Zhang, Min, Wei, Dongguang, Stueber, Dirk, Taratula, Oleh, Minko, Tamara, He, Huixin

    “…Co‐delivery of Doxorubicin and siRNAs by mesoporous silica nanoparticles into multidrug‐resistance cancer cells with minimal premature release significantly…”
    Get full text
    Journal Article
  10. 10

    Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells by Skupin-Mrugalska, Paulina, Minko, Tamara

    Published in Pharmaceutics (30-09-2020)
    “…Osimertinib (OSI, AZD9291), is a third-generation, irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that selectively…”
    Get full text
    Journal Article
  11. 11

    Shape effects of filaments versus spherical particles in flow and drug delivery by Geng, Yan, Dalhaimer, Paul, Discher, Dennis E, Cai, Shenshen, Tsai, Richard, Tewari, Manorama, Minko, Tamara

    Published in Nature nanotechnology (01-04-2007)
    “…Interaction of spherical particles with cells and within animals has been studied extensively, but the effects of shape have received little attention. Here we…”
    Get full text
    Journal Article
  12. 12

    Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer by Saad, Maha, Garbuzenko, Olga B, Minko, Tamara

    Published in Nanomedicine (London, England) (01-12-2008)
    “…To develop a novel nanomedicine approach for the treatment of multidrug-resistant (MDR) cancer by combining an anticancer drug and suppressors of cellular…”
    Get more information
    Journal Article
  13. 13

    Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA by Taratula, Oleh, Garbuzenko, Olga B., Chen, Alex M., Minko, Tamara

    Published in Journal of drug targeting (01-12-2011)
    “…A tumor targeted mesoporous silica nanoparticles (MSN)-based drug delivery system (DDS) was developed for inhalation treatment of lung cancer. The system was…”
    Get full text
    Journal Article
  14. 14

    LHRH-Targeted Drug Delivery Systems for Cancer Therapy by Li, Xiaoning, Taratula, Oleh, Taratula, Olena, Schumann, Canan, Minko, Tamara

    Published in Mini reviews in medicinal chemistry (01-01-2017)
    “…Targeted delivery of therapeutic and diagnostic agents to cancer sites has significant potential to improve the therapeutic outcome of treatment while…”
    Get more information
    Journal Article
  15. 15

    Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog by Gu, Xin, Majumder, Joydeb, Taratula, Olena, Kuzmov, Andriy, Garbuzenko, Olga, Pogrebnyak, Natalia, Minko, Tamara

    “…A novel nanotechnology-based drug delivery system (DDS) targeted at pancreatic cancer cells was developed, characterized, and tested. The system consisted of…”
    Get full text
    Journal Article
  16. 16

    Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer by Yin, Perry T, Shah, Shreyas, Pasquale, Nicholas J, Garbuzenko, Olga B, Minko, Tamara, Lee, Ki-Bum

    Published in Biomaterials (01-03-2016)
    “…Abstract Stem cell-based gene therapies, wherein stem cells are genetically engineered to express therapeutic molecules, have shown tremendous potential for…”
    Get full text
    Journal Article
  17. 17

    Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges by Pozharov, Vitaly P, Minko, Tamara

    Published in Pharmaceutics (05-01-2023)
    “…Over the past decades, many drugs based on the use of nanotechnology and nucleic acids have been developed. However, until recently, most of them remained at…”
    Get full text
    Journal Article
  18. 18

    In Vivo Evaluation of Nose-to-Brain Delivery of Liposomal Donepezil, Memantine, and BACE-1 siRNA for Alzheimer's Disease Therapy by Lee, David, Shen, Andrew M, Shah, Milin, Garbuzenko, Olga B, Minko, Tamara

    “…Our study took an innovative approach by evaluating, in vivo, the efficacy of intranasal (IN) administration of liposomal formulations of donepezil, memantine,…”
    Get full text
    Journal Article
  19. 19

    Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance by Garbuzenko, Olga B, Saad, Maha, Pozharov, Vitaly P, Reuhl, Kenneth R, Mainelis, Gediminas, Minko, Tamara

    “…Development of cancer cell resistance, low accumulation of therapeutic drug in the lungs, and severe adverse treatment side effects represent main obstacles to…”
    Get full text
    Journal Article
  20. 20

    Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells by Romaniuk-Drapala, Aleksandra, Skupin-Mrugalska, Paulina, Garbuzenko, Olga, Hatefi, Arash, Minko, Tamara

    Published in Cancer cell international (12-08-2024)
    “…Olaparib is a PARP inhibitor inducing synthetic lethality in tumors with deficient homologous recombination (HRD) caused by BRCA1/2 mutations. The FDA has…”
    Get full text
    Journal Article